参考文献/References:
[1]. Benjamin EJ,Muntner P,Alonso A,et al. Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association[J]. Circulation,2019,139(10):e56-e528.
[2]. Gumprecht J,Domek M,Lip GYH,et al. Invited review:hypertension and atrial fibrillation:epidemiology,pathophysiology,and implications for management[J].?J Hum Hypertens,2019,33(12):824-836.
[3]. Gorenek B,Pelliccia A,Benjamin EJ,et al. European Heart Rhythm Association(EHRA)/European Association of Cardiovascular Prevention and Rehabilitation(EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society(HRS) and Asia Pacific Heart Rhythm Society(APHRS)[J]. Europace.2017,19:190-225.
[4]. Krittayaphong R,Rangsin R,Thinkhamrop B,et al. Prevalence and associating factors of atrial fibrillation in patients with hypertension:a nation-wide study[J]. BMC Cardiovasc Disord,2016,16:57.
[5]. Rahman F,Yin X,Larson MG,et al. Trajectories of risk factors and risk of new-onset atrial fibrillation in the Framingham Heart Study[J]. Hypertension,2016,68(3):597-605.
[6]. O’Neal WT, Soliman EZ, Qureshi W, et al. Sustained pre-hypertensive blood pressure and incident atrial fibrillation:the Multi-Ethnic Study of Atherosclerosis[J]. J Am Soc Hypertens,2015,9(3):191-196.
[7]. 王艳秀,刘爱华,邢爱君,等. 累积血压暴露对新发心房颤动的预测价值[J]. 中国动脉硬化杂志,2019,27(4):354-358.
[8]. Thomas MC,Dublin S,Kaplan RC,et al. Blood pressure control and risk of incident atrial fibrillation [J]. Am J Hypertens ,2008,21(10):1111-1116.
[9]. Vemulapalli S,Inohara T,Kim S,et al. Blood Pressure control and cardiovascular outcomes in patients with atrial fibrillation(from the ORBIT-AF Registry)[J]. Am J Cardiol,2019,123(10):1628-1636.
[10]. Mitchell GF,Vasan RS,Keyes MJ,et al. Pulse pressure and risk of new-onset atrial fibrillation [J]. JAMA,2007,297(7):709-715.
[11]. Hermida RC,Ayala DE,Fernndez JR,et al. Sleep-time?blood pressure:prognostic?value?and?relevance?as a therapeutic target for cardiovascular risk reduction[J]. Chronobiol Int,2013,30(1-2):68-86.
[12]. Coulson JM. The relationship between blood pressure variability and catecholamine metabolites:a pilot study[J]. J Hum Hypertens,2015,29(1):50-52.
[13]. Proietti M,Romiti GF,Olshansky B,et al. Systolic blood pressure?visit-to-visit?variability?and major?adverse?outcomes in?atrial fibrillation:the AFFIRM study(Atrial Fibrillation?Follow-Up?Investigation?of?Rhythm Management)[J]. Hypertension,2017,70(5):949-958.
[14]. Verdecchia P, Angeli F, Gentile G,et al. More versus less intensive blood pressure-lowering strategy:cumulative evidence and trial sequential analysis[J]. Hypertension,2016,68(3):642-653.
[15]. Soliman EZ,Rahman AF,Zhang ZM,et al. Effect of intensive blood pressure lowering on the risk of atrial fibrillation[J]. Hypertension,2020,75(6):1491-1496.
[16]. Kim SJ,Choisy SC,Barman P,et al. Atrial remodeling and the substrate for atrial fibrillation in rat hearts with elevated afterload[J]. Circ Arrhythm Electrophysiol,2011,4(5):761-769.
[17]. Hohl M,Lau DH,Muller A,et al. Concomitant obesity and metabolic syndrome add to the atrial arrhythmogenic phenotype in male hypertensive rats[J]. J Am Heart Assoc,2017,6(9):e006717.
[18]. Chatterjee S,Bavishi C,Sardar P,et al. Meta-analysis of left ventricular hypertrophy and sustained arrhythmias[J]. Am J Cardiol,2014,114(7):1049-1052.
[19]. Jalife J,Kaur K. Atrial remodeling,fibrosis,and?atrial fibrillation[J]. Trends Cardiovasc Med,2014,25(6):475-484.
[20]. 师慧,赵璐露,杜云蕙,等.经脊髓电刺激房颤模型犬血清肾素-血管紧张素-醛固酮系统的变化及其对房颤的抑制作用[J].吉林大学学报(医学版),2019,45(3):511-517.
[21]. Seccia TM,Caroccia B,Adler GK,et al. Arterial hypertension,atrial fibrillation,and hyperaldosteronism:the triple trouble[J]. Hypertension,2017,69(4):545-550.
[22]. SPRINT Research Group,Wright JT Jr,Williamson JD,et al. A randomized trial of intensive versus standard blood-pressure control [J]. N Engl J Med,2015,373(22):2103-2116.
[23]. Soliman EZ,Byington RP,Bigger JT,et al. Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with diabetes mellitus:action to control cardiovascular risk in diabetes blood pressure trial[J]. Hypertension,2015,66(6):1123-1129.
[24]. Gepner AD,Tedla Y,Colangelo LA,et al. Progression of carotid arterial stiffness with treatment of hypertension over 10 years:the Multi-Ethnic Study of Atherosclerosis[J].?Hypertension,2017,69(1):87-95.
[25]. Abed HS,Wittert GA,Leong DP,et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation:a randomized clinical trial[J]. JAMA,2013,310(19):2050-2060.
[26]. Pathak RK,Middeldorp ME,Lau DH,et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation:the ARREST-AF cohort study[J]. J Am Coll Cardiol,2014,64(21):2222-2231.
[27]. Parkash R,Wells GA,Sapp JL,et al. Effect of aggressive blood pressure control on the recurrence of atrial fibrillation after catheter ablation: a randomized, open-label clinical trial(SMAC-AF[Substrate Modification With Aggressive Blood Pressure Control]). Circulation,2017,135(19):1788-1798.
[28]. Steinberg JS,Shabanov V,Ponomarev D,et al. Effect of renal denervation and catheter ablation vs catheter ablation alone on atrial fibrillation recurrence among patients with paroxysmal atrial fibrillation and hypertension:the ERADICATE-AF randomized clinical trial[J]. JAMA,2020,323(3):248-255.
[29]. Vemulapalli S,Hellkamp AS,Jones WS,et al. Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation:Results from the ROCKET AF Trial[J]. Am Heart J,2016,178:74-84.
[30].[30] Maeda T,Nishi T,Funakoshi S,et al. Residual risks of ischaemic stroke and systemic embolism among atrial fibrillation patients with anticoagulation:large-scale real-world data(F-CREATE project)[J]. Heart,2020,Aug 14,heartjnl-2020-317299.DOI:10.1136/heartjnl-2020-317299.Online ahead of print.
[31].[31] Kim D,Yang PS,Jang E,et al. Blood pressure control and dementia risk in midlife patients with atrial fibrillation[J]. Hypertension,2020,75(5):1296-1304.
[32].[32] B?hm M,Brueckmann M,Eikelboom JW,et al. Cardiovascular outcomes,bleeding risk,and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin:data from the RE-LY trial[J]. Eur Heart J,2020,41(30):2848-2859.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(3):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(3):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(3):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[6]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[7]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[8]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(3):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[9]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[10]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(3):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[11]周超飞 郭毅 邓珏琳.H型高血压与心房颤动的关系研究进展[J].心血管病学进展,2019,(9):1205.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.005]
ZHOU ChaofeiGUO YiDENG Juelin.H-type Hypertension and Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(3):1205.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.005]
[12]史云聪,王立立 郭艺芳.维生素D与心血管疾病相关性研究进展[J].心血管病学进展,2020,(8):826.[doi:10.16806/j.cnki.issn.1004-3934.20.08.011]
SHI YuncongWANG LiliGUO Yifang.Vitamin D And Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(3):826.[doi:10.16806/j.cnki.issn.1004-3934.20.08.011]
[13]李英 刘兴鹏.常见心血管病服药依从性[J].心血管病学进展,2020,(10):1016.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.000]
LI Ying,LIU Xingpeng.Medication Adherence For Common Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2020,(3):1016.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.000]
[14]陈建福 陈灿.血压目标范围内时间与心血管疾病关系的研究进展[J].心血管病学进展,2024,(7):617.[doi:10.16806/j.cnki.issn.1004-3934.2024.07.010]
CHEN Jianfu,CHEN Can.The Relationship Between Time in Target Range and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2024,(3):617.[doi:10.16806/j.cnki.issn.1004-3934.2024.07.010]